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Abstract
The 39- to 42-residue amyloid b (Ab) peptide is deposited in extracellular fibrillar plaques in the brain of patients suffering
from Alzheimer’s Disease (AD). Vaccination with these peptides seems to be a promising approach to reduce the plaque
load but results in a dominant antibody response directed against the N-terminus. Antibodies against the N-terminus will
capture Ab immediately after normal physiological processing of the amyloid precursor protein and therefore will also
reduce the levels of non-misfolded Ab, which might have a physiologically relevant function. Therefore, we have targeted
an immune response on a conformational neo-epitope in misfolded amyloid that is formed in advance of Ab-aggregation. A
tetanus toxoid-conjugate of the 11-meric cyclic peptide Ab(22–28)-YNGK9 elicited specific antibodies in Balb/c mice. These
antibodies bound strongly to the homologous cyclic peptide-bovine serum albumin conjugate, but not to the homologous
linear peptide-conjugate, as detected in vitro by enzyme-linked immunosorbent assay. The antibodies also bound—
although more weakly—to Ab(1–42) oligomers as well as fibrils in this assay. Finally, the antibodies recognized Ab deposits
in AD mouse and human brain tissue as established by immunohistological staining. We propose that the cyclic peptide
conjugate might provide a lead towards a vaccine that could be administered before the onset of AD symptoms. Further
investigation of this hypothesis requires immunization of transgenic AD model mice.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder and
the most common cause of dementia in elderly [1,2]. A
characteristic of the disease is formation of plaques in the brain
or in brain blood vessels. These plaques originate from a
membrane-bound protein, amyloid precursor protein (APP). An
a-helical fragment of 39–42 amino acid residues is cleaved by b-
and c-secretases from APP thus forming a soluble amyloid b (Ab)
peptide. Soluble Ab initially adopts an extended conformation but
at high concentrations, soluble Ab will undergo conformational
changes and form oligomers, protofibrils, and fibrils. In AD,
fibrillar Ab is deposited in the brain as amyloid plaques, which is
one of the main neuropathological hallmarks of the disease.
However, accumulating studies suggest that the soluble oligomeric
Ab instead of insoluble Ab in amyloid plaques is the culprit in AD
[3–8] and therapeutic approaches aimed at preventing the
formation of these oligomeric isoforms may be able to reduce
the progression of the disease. In line with this concept,
immunization of transgenic mice [9] with a suspension of ‘‘pre-
aggregated’’ Ab(1–42) and the adjuvant quillaja saponin 21
appeared to be beneficial. Based on these results, a phase I
clinical trial was started. Antibodies present in human sera
recognized plaques and Ab deposits in brain blood vessels [10].
The antibodies did not recognize APP or soluble Ab. In the
following phase II clinical trial, 20% of the vaccine recipients
generated anti-Ab antibody titers. Unfortunately, this trial had to
be terminated since 6% of the patients developed meningoen-
cephalitis as a vaccine-related side effect. This side effect was
caused by a cellular inflammatory reaction, attributed to a T
helper cell type 1 response to epitopes located in the central and C-
terminal part of Ab(1–42) [11,12].
Multiple ongoing studies aim at improving the Ab vaccination
strategy [13–18]. The use of T helper cell type 2 directing
adjuvants [19,20] or the use of formulations without any adjuvant
[21] are under investigation. In addition, it has been proposed to
use C-terminally truncated Ab peptides [22,23] or peptide mimics
(affitopes) of the N-terminus [24]. Antibodies induced by Ab(1–42)
are dominantly directed against the linear N-terminal epitope
[25,26], although generation of conformation-specific antibodies
against other regions within aggregated Ab has been reported
[27]. A disadvantage of a vaccine against the N-terminus of Ab is
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APP. It may not be without risk to administer such a vaccine
before onset of symptoms of AD.
By targeting an immune response exclusively on misfolded Ab
the undesired response against the N-terminus of Ab may be
avoided all together. A structural model of fibrillar Ab(1–42)
predicts folding of monomeric Ab(1–42) into a cross-b unit. Two
antiparallel extended b-strands, residues 11–25 and 28–42, are
connected via a sharp bend around amino acid residues S26 and
N27 [28]. Fig. 1 shows a simplification of the original model. A
recent study of a particular oligomer of N-Met-Ab(1–42) suggests a
bend around the sequence V
24-G-S-N
27 [29].
The models of folded Ab show some resemblance with the b-
turn structure in surface loops of meningococcal outer membrane
protein PorA. Previously, we have stabilized the b-turn confor-
mation of small meningococcal peptides by adding an artificial
sequence YNGK9, in which K9 is a modified lysine residue for
selective conjugation to a carrier protein, followed by main chain
(‘‘head to tail’’) amide cyclization [30,31]. Likewise, it appeared
possible to prepare small cyclic peptides mimicking the turn in
folded Ab. A panel of cyclic decameric and undecameric peptides
spanning six or seven residues from the region 21–31 of Ab and
YNGK9 was prepared and conjugated to tetanus toxoid (TTd).
The conjugates were used for immunization of mice. A tetanus
toxoid-conjugate of one of the peptides, cyclo[Ab(22–28)-




Oligomeric (<35 kD) and fibrillar Ab(1–42) were prepared
according to published procedures [32]. A well-established method
[33] was used for synthesis of a panel of cyclic decameric and
undecameric peptides spanning six or seven residues from the
region 21–31 (AEDVG
25SNKGA
30I) of Ab (i.e. 23–28, 24–29, 25–
30, 21–27, 22–28, 23–29, 24–30, and 25–31) and the artificial
stabilizing sequence YNGK9. Linear Ac-K9-Ab(21–31)-NH2 was
prepared to serve as control. The peptides obtained were
conjugated to tetanus toxoid (TTd) to give experimental vaccines
or to bovine serum albumin (BSA) to give coating antigens for
enzyme-linked immunosorbent assay (ELISA ) [34].
Immunization of mice
Balb/c mice were immunized twice with oligomeric or fibrillar
Ab(1–42) without adjuvant or with the different amyloid peptide/
TTd-conjugates using aluminum phosphate as adjuvant. The
pooled sera from each group immunized with peptide conjugate
were analyzed by ELISA using plain TTd, homologous peptide/
BSA-conjugate and oligomeric or fibrillar Ab(1–42) as coating
antigens. The sera showed a good antibody titer against TTd and




Six out of eight pooled anti-cyclo-Ab peptide antisera were not
cross-reactive with oligomeric or fibrillar Ab(1–42) in ELISA or a
dot blot assay. Antibodies against cyclo[Ab(23–29)-YNGK9]
showed a weak cross-reactivity. However, anti-cyclo[Ab(22–28)-
YNGK9] antibodies were strongly cross-reactive with oligomeric
or fibrillar Ab(1–42) in ELISA (Fig. 2) and the antibodies
recognized Ab deposits in AD mouse and human brain tissue
(Fig. 3). The anti-peptide antibodies did not recognize full length
APP in Western blot assay (Fig. 4).
The cyclization of the peptide was essential to produce a
functional antigen. Conjugates of linear control peptides, i.e. Ac-
K9-Ab(21–31)- NH2 or the fully homologous Ac-K9-Ab(22–28)-
YNG-NH2, induced good anti-peptide antibody titers but the
antibodies failed to recognize oligomeric or fibrillar Ab(1–42)
(Fig. 2). The incorporation of the artificial sequence YNGK9 in the
cyclopeptide was essential to mimic the turn in folded Ab(1–42).
Incorporation of the sequence GAIK9, i.e. Ab(29–31)-K9, instead
of YNGK9 did not provide a turn-mimicking peptide, since
antibodies against cyclo[Ab(22–31)-K9] were not functional.
Figure 1. Early folding of human amyloid b (Ab), around S26 and N27. The figure is a simplification of the model designed by Olofsson et al.
[28]. Residues in red are solvent accessible; residues in blue (and to a lesser extent in gray) are shielded from the solvent. The peptide cyclo[Ab(22–
28)-YNGK9] is a mimic for misfolded Ab. YNGK9 is a turn-stabilizing sequence and K9 is a side-chain-modified lysyl residue for selective conjugation to
a protein carrier. Other YNGK9-containing cyclic peptides prepared (23–28, 24–29, 25–30, 21–27, 22–28, 23–29, 24–30, and 25–31) did not mimic
misfolded Ab.
doi:10.1371/journal.pone.0019110.g001
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cific for the common Ab sequence. Amyloid b with the Dutch,
Arctic, or Italian mutations (E22Q, E22G, or E22K, respectively)
was not recognized. Unrelated but partially homologous proteins
like the islet amyloid polypeptide (amylin)or the human Wiskott-
Aldrich Syndrome protein (WASP) were also not recognized (data
not shown).
Finally, antibodies elicited with oligomeric or fibrillar Ab(1–42)
were non-reactive with cyclo[Ab(22–28)-YNGK9]-BSA. This was
expected since antibodies induced by Ab(1–42) are directed
against the N-terminus [25,26].
The cross-reactivity of anti-cyclo[Ab(22–28)-YNGK9] antibod-
ies with oligomeric Ab(1–42) was confirmed after a second
immunization experiment. Individual sera of mice immunized
with cyclo[Ab(22–28)-YNGK9]-TTd were analyzed this time. All
sera (8/8) gave a good response against TTd and the homologous
peptide (titers 10
4–10
5, data not shown), but not all individual sera
were clearly cross-reactive with oligomeric or fibrillar Ab(1–42).
Five sera showed titers $2000 (Fig. 5), whereas one serum showed
no response (titer,100). Two immunizations with oligomeric
Ab(1–42) gave two sera with titers as high as 40610
3 and 50610
3
on the homologous coating. Three titers were considered to be
intermediate (2000–8000) and three titers were low (100–2000).
Two immunizations with fibrillar Ab(1–42) gave only two sera
with titers $2000 on the homologous coating, two very low
responders and four non-responders (titer,100). Poor responsive-
ness to aggregated Ab(1–42) was found earlier in clinical and
animal studies [35,36].
In conclusion, cyclo[Ab(22–28)-YNGK9] mimics a conforma-
tional epitope in folded Ab(1–42) that normally does not induce an
antibody response. Cyclo[Ab(22–28)-YNGK9]-conjugate may be
an interesting vaccine candidate against AD. Since the response is
directed specifically to misfolded Ab, it is unlikely that vaccination
will interfere with normal physiological processing of the amyloid
precursor protein. Thus, vaccination might be possible at an early
stage of AD symptoms or before. This seems to be indicated since
plaque deposits have already reached a near maximum level at a
mild stage of AD [37].
Further studies will aim at improvement of the immune
response to cyclo[Ab(22–28)-YNGK9]-TTd by variation of the
 
Figure 2. Binding of anti-cyclopeptide antibodies to oligomeric amyloid b (Ab) as determined by ELISA. Threefold serial dilutions
(starting from 1/150) of pooled antisera obtained were tested. Antisera were raised by immunization with oligomeric (black m) or fibrillar (black &)
Ab(1–42) and TTd-conjugates of cyclo[Ab(22–28)-YNGK9] (red m) or linear K9-Ab(22–28)-YNG (red &). Monoclonal antibody 6E10 (greenN) served as
control. Antibody binding to fibrillar Ab(1–42) gave comparable results.
doi:10.1371/journal.pone.0019110.g002
Figure 3. Immunohistochemical staining of brain tissue. A, a brain section (hippocampus) of an 85-year-old female AD patient (NBB 1999-030)
was stained with mouse anti-cyclo[Ab(22–28)-YNGK9] serum and (B) co-stained with an antibody against APP (6E10). The neuropathological diagnosis
of the is patient is Braak stage for neurofibrillary tangles 6 and for amyloid B [43]. C, immunostaining of a plaque-loaded cortex of a 9 month old
APPswe/PS1dE9 transgenic mouse.
doi:10.1371/journal.pone.0019110.g003
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administrations, preferably in transgenic AD model mice.
Materials and Methods
Ethics statement
Tissue from AD patients was obtained from the Netherlands
Brain Bank (NBB; Amsterdam, The Netherlands). The NBB
performs brain autopsies with short post-mortem intervals, and the
brain donors have given written informed consent for using the
tissue and for accessing the extensive neuropathological and
clinical information for scientific research, in compliance with
ethical and legal guidelines [38]. The study was approved by the
independent Review Board (‘‘Medisch Ethische Toetsingscom-
missie, METc’’) of the VU University Medical Center, Amster-
dam, The Netherlands.
Morphological studies of mouse brain tissue were approved by
the Ethical Committee on Animal Experiments of the Royal
Netherlands Academy of Arts and Sciences (approval ID: NIN
06.51).
Immunization of mice was approved by the Ethical Committee
on Animal Experiments of the National Institute of Public Health
and the Environment (approval ID: 2007 00331 and 2008
00179), as required under Dutch Law on the use of laboratory
animals. All efforts were made to minimize suffering of the
animals.
Materials
Human Ab(1–42) (Fig. 1), hAb(1–40/42) analogues, and hIAPP
were purchased from AnaSpec (Freemont, CA, USA). AlPO4
suspension (1.5 mg/ml), pH 7.0, and tetanus toxoid (TTd) were
produced by the RIVM. Monoclonal antibody 6E10 against
Ab(1–17), was purchased from Abcam (Cambridge, MA, USA) or
Covance Research Products, Dedham, MA, USA).
Disaggregation of Ab(1–42)
Lyophilized Ab(1–42) was dissolved in trifluoroacetic acid at a
concentration of 1.0 mM, left to stand at room temperature for
1 h and dried under a stream of nitrogen and, thereafter, in a
vacuum (1 mm Hg) for 15 min. The peptide was then redissolved
in hexafluoroisopropanol at a concentration of 1.0 mM and, after
1 h of incubation at room temperature, dried as described above
[39]. The peptide was stored at 220uC for 18–20 h.
Preparation of oligomeric or fibrillar Ab(1–42)
Disaggregated of Ab(1–42) was dissolved in dimethyl sulfoxide
at a concentration of 5.0 mM, diluted 50-fold with either
phosphate buffered saline (PBS), pH 7.2, or 10 mM hydrochloric
acid. The solution in PBS was incubated at 4uC for 24 h (to give
oligomers), whereas the solution in 10 mM HCl was incubated at
37uC for 24 h (to give fibrils) [32].
Peptide synthesis, purification, and conjugation
The a-(2,4-dimethoxybenzyl) ester of N
a-fluorenylmethoxycar-
bonyl-L-aspartic acid (Fmoc-Asp-ODmb) was coupled through its
side-chain to a polymer for the synthesis of peptide amides (for
later conversion of the starting Asp into Asn). Synthesis of cyclic
peptides, like cyclo[GK9EDVGSNKYN];cyclo[EDVGSN-
KYNGK9] in which K9 is N
e-(S-acetylmercaptoacetyl)lysyl, was
then performed as described earlier [33]. The following Ab-
derived and YNGK9-extended cyclopeptides were prepared: 23–
28, 24–29, 25–30, 21–27, 22–28, 23–29, 24–30, and 25–31.
Linear Ac-K9-Ab(22–31)-NH2 and linear Ac-K9-Ab(22–28)-YNG-
NH2 were also prepared. The peptides were purified by reverse-
phase high performance liquid chromatography and coupled to
either bromoacetylated tetanus toxoid or maleimidyl-modified
bovine serum albumin (BSA) (modifying reagent: NHS-PEO2-
Maleimide, Pierce) [34].
Immunization of mice
Groups of eight female Balb/c mice of 6–8 weeks of age were
immunized with 25 mg oligomeric or fibrillar Ab(1–42) in 0.3 ml
phosphate buffered saline (PBS), pH 7.2, without adjuvant or with
50 mg of peptide/TTd-conjugate and 75 mg of AlPO4 in 0.3 ml
PBS on days 0 and 28. The mice were bled on day 42 under
oxygen/nitrous oxide/isoflurane anesthesia.
Western blot
Human carcinoma SW13 cells [40] were transfected with
APP
695wt (wild type) and APP
695swe (Swedish mutation) and
proteins were isolated by homogenization in 0.1 M NaCl, 0.01 M
Tris HCl, 0.001 M EDTA, pH 7.6, with proteinase inhibitors.
The samples were supplemented with 26loading buffer (100 mM
Tris pH 6.8, 4% SDS, 20% glycerol, 0.2 M DTT, 0.006%
bromophenol blue) and run on a 7.5% SDS-PAGE gel. The gel
was semi-dry blotted on nitrocellulose and probed overnight with
the 6E10 antibody (1:1000) or the mouse anti-cyclo[Ab(22–28)-
YNGK9] serum (1:500). After washing, the blots were incubated
with anti-mouse Cy5 (1:300), bands were visualized with the
Odyssey Infrared Imaging System.
Figure 4. Western blot of a lysate of SW13 adrenal cells
transfected with amyloid precursor protein (APP). The cells were
transfected with either human APP
695wt (wild type) or with APP
695swe
(Swedish mutation). Monoclonal antibody 6E10 is specific for the largely
unstructured N-terminus of amyloid b (Ab) and recognized both APPs
(amino acid residues 2–8 in Ab correspond to residues 598–604 in
APP
695). Anti-cyclo[Ab (22–28)-YNGK9] antibodies stained neither of the
APPs under the denaturing conditions of the assay and thus seem to
recognize a conformational epitope in Ab.
doi:10.1371/journal.pone.0019110.g004
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Dilutions of cell lysates (WASP
pos HL60 cells and WASP
neg
Vero cells) in PBS were spotted (1 ml/spot) on polyvinylidene
difluoride membrane (Immobilon-P, pore size 0.45 mM, Milli-
pore). The blots were incubated with mouse anti-cyclo[Ab(22–28)-
YNGK9] serum, control monoclonal antibody 6E10, or polyclonal
anti-WASP antibodies. After washing, the blots were incubated
with horseradish peroxidase-conjugated 2
nd antibody, and visual-
ized with GZ11 signal reagent [41].
ELISA
Microtiter plates (Greiner 655092) were coated with Ab(1–42)
or peptide-BSA conjugates. Freshly prepared Ab(1–42) oligomers
or fibrils were diluted to a final concentration of 2.5 mM (11.3 mg/
ml) in 0.04 M sodium carbonate/bicarbonate buffer, pH 9.7.
Peptide-BSA conjugates in phosphate buffered saline, pH 7.2
(PBS), had a total protein concentration of 0.5 mg/ml. Aliquots
(100 ml) of these solutions were transferred into wells of the plates.
The plates were incubated for 90 min at 37uC. The plates were
further processed as described earlier [42]. Titers were calculated
as the reciprocal serum dilution at 50% of the maximum optical
density (OD50).
Immunohistochemical staining
Human brain sections of the hippocampus of several donors
with Alzheimer disease, Braak 5 or 6 [43], were used (Netherlands
Brain Bank). In addition, brain sections of 9 month old APPswe/
PS1dE9 [42] mice with a significant plaque deposition were used.
Cryosections (10 mm) were cut from unfixed, directly frozen tissue,
thaw-mounted, dried for 1 hour and stored in a sealed box at
220 C. For immunostaining, sections were fixed in 4% PFA-PBS
solution for 10 min, washed in 0.05 M phosphate buffer (PB) for
10 min with 2 exchanges and blocked with 10% normal donkey
serum (NDS) +0.4% Triton X-100 in 0.05 M PB for 1 hour at
RT. The blocking solution was discarded and diluted mouse sera
(1:300; first antibody) in 3% NDS +0.4% Triton X-100 in 0.05 M
Figure 5. IgG response of individual Balb/c mice against Ab (1–42) as determined by ELISA. As indicated on the x-axis, groups of eight
mice were immunized with cyclo[Ab (22–28)-YNGK9]-TTd, oligomeric Ab(1–42), or fibrillar Ab (1–42). A, coating antigen: oligomeric Ab (1–42);
B, coating antigen: fibrillar Ab (1–42). A mouse with a serum titer #100 is considered to be a non-responder. The two titers out of range in the right
panel of A have values of 40610
3 and 50610
3. The figure demonstrates that anti- cyclo[Ab (22–28)-YNGK9] antibodies recognize oligomeric and
fibrillar Ab (1–42).
doi:10.1371/journal.pone.0019110.g005
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with 0.05 M PB; at least 30 min with one or more exchanges.
Then sections were incubated with Donkey-anti-Mouse ,Cy3
1:1400 in 0.05 M PB for 2 hours. Sections were washed with
0.05 M PB; at least 30 min with one or more exchanges. Sections
were sealed in Vectashield with Dapi (Vector). Mouse Monoclonal
6E10 to beta amyloid 3–8 (Signet-Covance) was used as positive
control (1:15,000).
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